InvestorsHub Logo
Post# of 1031
Next 10
Followers 3
Posts 391
Boards Moderated 0
Alias Born 07/23/2017

Re: None

Wednesday, 12/13/2017 10:29:00 AM

Wednesday, December 13, 2017 10:29:00 AM

Post# of 1031
DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot (PR Newswire)

Excerpt: In consideration for such assignment, Indivior has made an upfront non-refundable payment to DURECT of $12.5 million, and has also agreed to make an additional $5 million payment to DURECT contingent upon NDA approval of RBP-7000, as well as quarterly earn-out payments that are based on a single digit percentage of U.S. net sales for certain products covered by the assigned patent rights, including RBP-7000. The patent rights include granted patents extending through at least 2026.

I read tea leaves. Keeping my teacup full.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRRX News